| Identification | Back Directory | [Name]
2-Amino-1-[2-(4-fluorophenyl)-3-[(4-fluorophenyl)amino]-5,6-dihydro-8,8-dimethylimidazo[1,2-a]pyrazin-7(8H)-yl]ethanone | [CAS]
1261113-96-5 | [Synonyms]
KAF-156
GNF-156)
Ganaplacide
(KAF156
2-Amino-1-[2-(4-fluorophenyl)-3-[(4-fluorophenyl)amino]-5,6...
2-Amino-1-[2-(4-fluorophenyl)-3-[(4-fluorophenyl)amino]-5,6-dihydro-8,8-dimethylimidazo[1,2-a]pyrazin-7(8H)-yl]ethanone
Ethanone, 2-amino-1-[2-(4-fluorophenyl)-3-[(4-fluorophenyl)amino]-5,6-dihydro-8,8-dimethylimidazo[1,2-a]pyrazin-7(8H)-yl]- | [Molecular Formula]
C22H23F2N5O | [MDL Number]
MFCD28502124 | [MOL File]
1261113-96-5.mol | [Molecular Weight]
411.45 |
| Hazard Information | Back Directory | [Uses]
GNF-156 is used in the development process for discovery and clinical advancement of modern antimalarials. | [in vivo]
Ganaplacide (KAF156) displays cidal activity against mature Plasmodium falciparum gametocytes and thus blocks parasite transmission to Anopheles mosquitoes[1].
Ganaplacide (KAF156) (1-15 mg/kg; p.o.) is fully protective in a causal prophylactic mouse model of malaria[1]. | Animal Model: | Mice (causal prophylactic rodent malaria model)[1] | | Dosage: | 1-15 mg/kg | | Administration: | p.o. | | Result: | A single oral dose of 10 mg of KAF156/kg administered 2 h before infection was fully protective. |
|
|
|